scholarly journals Assessment of Oxaliplatin-induced Chronic Neuropathy and Anticancer Efficacy Through Pharmacokinetic and Toxicodynamic Evaluation of a Rat Model of Colorectal Cancer

2019 ◽  
Vol 39 (8) ◽  
pp. 4207-4213
Author(s):  
YUKAKO ITO ◽  
SHINJI KOBUCHI ◽  
WAKI TAKESADA ◽  
CHIHARU TAKAHASHI
Keyword(s):  
Colorectal Cancer ◽  
Rat Model ◽  
Anticancer Efficacy ◽  
Chronic Neuropathy

scholarly journals Antiproliferative Efficacy of N-(3-chloro-4-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine, DW-8, in Colon Cancer Cells Is Mediated by Intrinsic Apoptosis

Molecules ◽  
2021 ◽  
Vol 26 (15) ◽  
pp. 4417
Author(s):  
Rabin Neupane ◽  
Saloni Malla ◽  
Mariam Sami Abou-Dahech ◽  
Swapnaa Balaji ◽  
Shikha Kumari ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Cancer Cells ◽  
Cell Lines ◽  
Colon Cancer Cells ◽  
Apoptotic Pathway ◽  
Anticancer Efficacy ◽  
Colon Cell ◽  
Ic50 Values ◽  
Induced Apoptosis

A novel series of 4-anilinoquinazoline analogues, DW (1–10), were evaluated for anticancer efficacy in human breast cancer (BT-20) and human colorectal cancer (CRC) cell lines (HCT116, HT29, and SW620). The compound, DW-8, had the highest anticancer efficacy and selectivity in the colorectal cancer cell lines, HCT116, HT29, and SW620, with IC50 values of 8.50 ± 2.53 µM, 5.80 ± 0.92 µM, and 6.15 ± 0.37 µM, respectively, compared to the non-cancerous colon cell line, CRL1459, with an IC50 of 14.05 ± 0.37 µM. The selectivity index of DW-8 was >2-fold in colon cancer cells incubated with vehicle. We further determined the mechanisms of cell death induced by DW-8 in SW620 CRC cancer cells. DW-8 (10 and 30 µM) induced apoptosis by (1) producing cell cycle arrest at the G2 phase; (2) activating the intrinsic apoptotic pathway, as indicated by the activation of caspase-9 and the executioner caspases-3 and 7; (3) nuclear fragmentation and (4) increasing the levels of reactive oxygen species (ROS). Overall, our results suggest that DW-8 may represent a suitable lead for developing novel compounds to treat CRC.

scholarly journals Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models

2021 ◽  
Vol 22 (6) ◽  
pp. 3160
Author(s):  
Michal Kopczynski ◽  
Malgorzata Statkiewicz ◽  
Magdalena Cybulska ◽  
Urszula Kuklinska ◽  
Katarzyna Unrug-Bielawska ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cell Lines ◽  
Transmembrane Protein ◽  
Acquired Resistance ◽  
Protein A ◽  
Resistance Mechanism ◽  
Receptor Expression ◽  
Human Colorectal Cancer ◽  
Protein Activity ◽  
Anticancer Efficacy

TNF-related apoptosis-inducing ligand (TRAIL) is a type II transmembrane protein capable of selectively inducing apoptosis in cancer cells by binding to its cognate receptors. Here, we examined the anticancer efficacy of a recently developed chimeric AD-O51.4 protein, a TRAIL fused to the VEGFA-originating peptide. We tested AD-O51.4 protein activity against human colorectal cancer (CRC) models and investigated the resistance mechanism in the non-responsive CRC models. The quantitative comparison of apoptotic activity between AD-O51.4 and the native TRAIL in nine human colorectal cancer cell lines revealed dose-dependent toxicity in seven of them; the immunofluorescence-captured receptor abundance correlated with the extent of apoptosis. AD-O51.4 reduced the growth of CRC patient-derived xenografts (PDXs) with good efficacy. Cell lines that acquired AD-O51.4 resistance showed a significant decrease in surface TRAIL receptor expression and apoptosis-related proteins, including Caspase-8, HSP60, and p53. These results demonstrate the effectiveness of AD-O51.4 protein in CRC preclinical models and identify the potential mechanism underlying acquired resistance. Progression of AD-O51.4 to clinical trials is expected.

scholarly journals In vivo Recombinant Adenovirus-mediated p53 Gene Therapy in a Syngeneic Rat Model for Colorectal Cancer

2004 ◽  
Vol 19 (6) ◽  
pp. 834 ◽  
Author(s):  
Jeong-Heum Baek ◽  
Munna L Agarwal ◽  
Raymond R Tubbs ◽  
Alex Vladisavljevic ◽  
Hiroshi Tomita ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gene Therapy ◽  
Rat Model ◽  
Recombinant Adenovirus ◽  
P53 Gene

A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer

2013 ◽  
pp. n/a-n/a
Author(s):  
Shinji Kobuchi ◽  
Shota Kuwano ◽  
Kazuki Imoto ◽  
Kae Okada ◽  
Asako Nishimura ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Rat Model ◽  
Predictive Biomarker ◽  
Repeated Administration

Effect of Deoxycholic Acid on the Tumour Incidence, Distribution, and Receptor Status of Colorectal Cancer in the Rat Model

Digestion ◽  
1985 ◽  
Vol 31 (2-3) ◽  
pp. 77-81 ◽  
Author(s):  
J. Summerton ◽  
Nicola Goeting ◽  
G.A. Trotter ◽  
I. Taylor
Keyword(s):  
Colorectal Cancer ◽  
Rat Model ◽  
Deoxycholic Acid ◽  
Tumour Incidence ◽  
Receptor Status

Immunological Aspects of Photodynamic Therapy of Liver Tumors in a Rat Model for Colorectal Cancer ¶

2007 ◽  
Vol 78 (3) ◽  
pp. 235-240
Author(s):  
Frederieke H. Van Duijnhoven ◽  
Remco I. J. M. Aalbers ◽  
Jeroen P. Rovers ◽  
Onno T. Terpstra ◽  
Peter J. K. Kuppen
Keyword(s):  
Colorectal Cancer ◽  
Photodynamic Therapy ◽  
Rat Model ◽  
Liver Tumors

scholarly journals Astroglial changes in the zona incerta in response to motor cortex stimulation in a rat model of chronic neuropathy

IBRO Reports ◽  
2019 ◽  
Vol 6 ◽  
pp. S291
Author(s):  
Myeounghoon Cha ◽  
Kyeongmin Kim ◽  
Songyeon Choi ◽  
Bae Hwan Lee
Keyword(s):  
Motor Cortex ◽  
Rat Model ◽  
Zona Incerta ◽  
Motor Cortex Stimulation ◽  
Chronic Neuropathy

scholarly journals Lemongrass Extract Possesses Potent Anticancer Activity Against Human Colon Cancers, Inhibits Tumorigenesis, Enhances Efficacy of FOLFOX, and Reduces Its Adverse Effects

2019 ◽  
Vol 18 ◽  
pp. 153473541988915 ◽  
Author(s):  
Ivan Ruvinov ◽  
Christopher Nguyen ◽  
Benjamin Scaria ◽  
Caleb Vegh ◽  
Ola Zaitoon ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Anticancer Activity ◽  
Cancer Cells ◽  
Human Colon ◽  
Dependent Manner ◽  
Anticancer Efficacy ◽  
Colon Cancers ◽  
Induced Apoptosis

Current chemotherapeutics for metastatic colorectal cancers have limited success and are extremely toxic due to nonselective targeting. Some natural extracts have been traditionally taken and have shown anticancer activity. These extracts have multiple phytochemicals that can target different pathways selectively in cancer cells. We have shown previously that lemongrass ( Cymbopogon citratus) extract is effective at inducing cell death in human lymphomas. However, the efficacy of lemongrass extract on human colorectal cancer has not been investigated. Furthermore, its interactions with current chemotherapies for colon cancer is unknown. In this article, we report the anticancer effects of ethanolic lemongrass extract in colorectal cancer models, and importantly, its interactions with FOLFOX and Taxol. Lemongrass extract induced apoptosis in colon cancer cells in a time and dose-dependent manner without harming healthy cells in vitro. Oral administration of lemongrass extract was well tolerated and effective at inhibiting colon cancer xenograft growth in mice. It enhanced the anticancer efficacy of FOLFOX and, interestingly, inhibited FOLFOX-related weight loss in animals given the combination treatment. Furthermore, feeding lemongrass extract to APCmin/+ transgenic mice led to the reduction of intestinal tumors, indicating its preventative potential. Therefore, this natural extract has potential to be developed as a supplemental treatment for colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document